VJHemOnc Podcast

In this insightful discussion, Dr. Akshay Sharma, a hematologist at St. Jude Children’s Research Hospital, explores the cutting-edge field of gene therapy for sickle cell disease. He details key considerations for selecting patients, emphasizing organ function and pre-existing health conditions. The conversation highlights the complex benefits and challenges of gene therapy, including the risk of leukemia linked to lentiviral treatments. Additionally, Dr. Sharma addresses the evolving role of palliative care in enhancing patient comfort during such innovative therapies.

Experts share cutting-edge strategies to enhance CAR T-cell therapy effectiveness while minimizing side effects. Insightful discussions reveal how diet can impact treatment outcomes, highlighting surprising metabolites. Keynote talks explore accelerating CAR T-cell therapeutics using CRISPR technology. The challenges of improving access to these therapies in community settings are tackled, underscoring the importance of collaboration between healthcare providers to ensure patients receive optimal care.

Paolo Ghia, a leading expert in chronic lymphocytic leukemia (CLL) from Vita-Salute San Raffaele University, joins forces with Arnon Kater from the University of Amsterdam to discuss the latest ESMO clinical practice guidelines. They dive into innovative treatment strategies for relapsed CLL, including the use of the non-covalent BTK inhibitor pirtobrutinib and the promising roles of allogeneic stem cell transplantation and CAR T-cell therapy. The conversation also highlights the evolving landscape of therapies like BTK degraders and bispecific antibodies.

Join Damian Green, a leader in cellular immunotherapy at the University of Miami, and Rachid Baz, a myeloma specialist at Moffitt Cancer Center, as they dive into the latest breakthroughs in multiple myeloma treatments. They discuss the benefits and challenges of T-cell therapies, including managing side effects and improving access to treatment. There's also a focus on innovative therapies like bispecific antibodies, the importance of personalized medicine, and real patient stories that highlight transformative outcomes.

Lydia Scarfò, an expert in chronic lymphocytic leukemia from Milan, and Anna Schuh, a professor from the University of Oxford, share insights on the latest ESMO guidelines for CLL. They delve into diagnostic advancements, highlighting critical biomarkers and clinical practice variations between the US and Europe. The duo discusses evolving treatment strategies focusing on personalized medicine, patient preferences, and the significance of measurable residual disease. They also explore the debate over time-limited versus continuous regimens in enhancing patient outcomes.

Join Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital in Paris, as he dives into the latest advancements in preventing and managing graft-versus-host disease (GvHD). Learn about innovative therapies like Belumazidil and the complexities of CMV and HHV-6 infections after stem cell transplants. The discussion also highlights the potential of artificial intelligence in hematology, advocating for its role as a supportive tool for clinicians while ensuring compassionate patient care. It's a deep dive into the future of hematologic treatment!

Paolo Strati, an Associate Professor at MD Anderson Cancer Center, and Gloria Iacoboni, a hematologist at Vall d’Hebron Hospital, delve into therapy sequencing for relapsed/refractory non-Hodgkin lymphoma. They discuss innovations in diffuse large B-cell lymphoma, emphasizing the impact of CAR T-cell and bispecific therapies. The pair also tackles timing for CD19 therapy post-bendamustine and explores the evolving landscape of mantle cell lymphoma treatments, highlighting the role of BTK inhibitors and the importance of personalized therapy approaches.

Discover groundbreaking advancements in CAR T-cell therapy for lymphoma. Hear about CTX112, a next-gen allogeneic product showcasing impressive response rates and safety. Dive into the trials of trispecific CAR T-cells targeting multiple malignancies, highlighting a promising 70% overall response. Also discussed are innovative strategies like bisestronic therapies and a dose-dense approach that enhances treatment efficacy with minimal side effects. These insights from leading experts underscore the exciting future of lymphoma treatment.

Selina Luger, an expert in leukemias, and Curtis Lachowiez, a hematological malignancies authority, discuss groundbreaking strategies for optimizing induction therapy in acute myeloid leukemia. They delve into the exciting results of combining venetoclax with traditional chemotherapy, showcasing enhanced remission rates. Additionally, Luger shares insights from trials comparing FLT3 inhibitors, while Lachowiez highlights the potential of menin inhibitors like Ziftomenib. The conversation also touches on the effectiveness of CPX-351 and future advancement directions in AML treatment.

Join Krish Patel, an expert in mantle cell lymphoma from the Sarah Cannon Cancer Institute, and David Lewis from Plymouth University, as they discuss the groundbreaking role of BTK inhibitors in treating relapsed/refractory MCL. They explore innovative combination strategies to tackle resistance and enhance treatment efficacy. The conversation highlights the importance of personalized therapy and the evolving landscape of BTK inhibitor selection, particularly in the UK. Their insights reveal promising future directions in MCL management.